Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.
Descubre las innovadoras soluciones biofarmacéuticas y sanitarias integrales de Grifols centradas en el paciente.
Explore Grifols Poland, a leader in biotechnology and healthcare, dedicated to improving patient lives through innovative therapies and high-quality services.
Grifols is a global healthcare company that has enhanced the health and well-being of people around the world.
Join Grifols to create a lasting impact with your career. Explore opportunities that allow you to contribute to life-saving solutions and innovate for a healthier future.
Grifols is also a leader in transfusion medicine, helping ensure the safety of the world’s blood supply. In addition, we provide biological materials, including plasma, for life-science research and further manufacturing, and the company has a comprehensive portfolio of tools, information and services that enable hospitals to efficiently ...
We trace our roots back to 1909 when Dr. Josep Antoni Grifols i Roig founded the first analysis laboratory in Barcelona: Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos.
The sale of a minority stake of its U.S. Biopharma business by means of an initial public offering (IPO) would raise capital to strengthen the Group’s balance sheet, reduce debt and support investment in its strategic growth priorities, while allowing Grifols to maintain majority ownership of its U.S. Biopharma business The proposed transaction reinforces Grifols’ self-sufficiency vision ...
Contact Grifols for inquiries and support. Our team is here to assist you with information and resources tailored to your needs.
Explore Grifols France for cutting-edge pharmacovigilance and comprehensive medical information to enhance patient safety and treatment outcomes.
Não está no seu computador? Use uma janela de navegação privada para fazer login. Saiba como usar o modo visitante.
Bukan komputer Anda? Gunakan jendela penjelajahan rahasia untuk login. Pelajari lebih lanjut cara menggunakan Mode tamu
Get help with logging into your Instagram account: Find out how to navigate the login screen options, how to use Facebook to log into Instagram.
UPI: Race-based question removed from Kidney Donor Profile Index to improve transplant equity
July 8 (UPI) --In a move to improve kidney transplant equity, a new policy will remove a question about race from the Kidney Donor Profile Index because it "dishonors African American/Black donors." ...
Race-based question removed from Kidney Donor Profile Index to improve transplant equity
Yahoo Finance: 2025 ORGAN DONATION REPORT: The typical organ donor profile has changed since the beginning of the century
As the province gets set to mark National Organ and Tissue Donation Awareness Week, Transplant Québec is drawing up its 2025 report. Since the 2000s, the number of referrals, donors and transplanted ...
2025 ORGAN DONATION REPORT: The typical organ donor profile has changed since the beginning of the century
Renal & Urology News: KDPI Race Variable Found to Up Black Donor Kidney Discard Rate
kidney transplant container Removing the race coefficient from the KDPI may increase use of Black deceased donor kidneys, according to investigators. Kidneys recovered from Black deceased donors have ...
phillyvoice.com: Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
Healio: ‘Modest change’ can make ‘big impact’ if kids get donor kidneys with matching EBV status
Please provide your email address to receive an email when new articles are posted on . Less than 14% of EBV-negative children received a kidney from an EBV-negative donor. Many EBV-negative kidneys ...
‘Modest change’ can make ‘big impact’ if kids get donor kidneys with matching EBV status
RealClearScience: The Flawed Reason Why Kidneys From Black Donors Are More Likely to Be Thrown Away
The Flawed Reason Why Kidneys From Black Donors Are More Likely to Be Thrown Away
Many players have had their Throne and Liberty session halted by the profile login required error that has been popping up recently. In fact, it can freeze your game ...
Facebook profiles have become the de-facto identities of people across the internet. This is thanks, in large part, to Login With Facebook, the social network's universal login API, which allows users ...
The Globe and Mail: Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.
Grifols Refinances 2027 Debt and Extends Maturities with Multi-Billion Term Loan B Package
Yahoo Finance UK: Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Recent performance context for Grifols Grifols (BME:GRF) has drawn investor attention after a mixed run, with a modest 1 day gain, a negative move over the past week and month, and a deeper decline ...
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
The Corner: Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Link Securities | Grifols (GRF) plans to make an early repayment of €500 million of its 7.5% senior secured bonds maturing in 2030. This transaction would ...
Grifols plans to make early repayment of €500 million of its 7.5% secured bonds maturing in 2030
Jan 9 (Reuters) - Spanish drugmaker Grifols, whose shares slumped on Tuesday after hedge fund Gotham City Research questioned its accounts, has grown from a family-run blood testing lab founded in ...
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
Yahoo Finance: Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
We’re maintaining our $11.80/EUR 10.90 fair value estimates for Grifols Class B (nonvoting) shares following the news that Grifols family members and private equity firm Brookfield Capital Partners ...
Grifols (NASDAQ:GRFS) shares shot up by nearly 22% in the premarket session today. The surge followed an approach by its founding family and Brookfield to acquire and delist the Spanish pharmaceutical ...